NEXT GENERATION MIGRAINE THERAPIES
AMERICAN HEADACHE SOCIETY

Saturday, March 21, 2020
Seattle Marriott Waterfront
2100 Alaskan Way
Seattle, WA

Saturday, April 4, 2020
Sheraton Salt Lake City
150 West 500 South
Salt Lake City, UT

Saturday, May 16, 2020
Sheraton Grand Chicago
301 East North Water Street
Chicago, IL

#AHSNextGen

NO COST TO HEALTHCARE PROFESSIONALS!
All programs are scheduled from 7:45 am – 4:45 pm (subject to change)
NO COST TO HEALTHCARE PROFESSIONALS

The Next Generation Migraine Therapies program is being offered to healthcare professionals at NO COST and will focus on providing only new and clinically relevant information via a series of didactic lectures, reviews of case studies, and interactive question-and-answer periods that will enhance basic understanding and improve prescribing techniques.

CME Statement: AHS is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians. AHS takes responsibility for the content, quality, and scientific integrity of this CME activity. The American Headache Society® designates this live activity for a maximum of 7.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This Live activity, Next Generation Migraine Therapies, from 03/21/2020 - 05/16/2020, has been reviewed and is acceptable for up to 8.25 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For more information, please call 856-423-0043 or email AHSHQ@talley.com

For complete program information and to register, please visit www.AmericanHeadacheSociety.org

The Next Generation Migraine Therapies Program is Supported by an Education Grant from Allergan, Inc. and Lilly USA, LLC
Saturday, March 21, 2020
Seattle Marriott Waterfront
2100 Alaskan Way
Seattle, WA

Saturday, April 4, 2020
Sheraton Salt Lake City
150 West 500 South
Salt Lake City, UT

Saturday, May 16, 2020
Sheraton Grand Chicago
301 East North Water Street
Chicago, IL
EDUCATIONAL OBJECTIVES

Upon completion of this program, participants will be better able to:

• Recognize the lack of awareness of the basic science and therapeutic potential of CGRP mAbs in the prevention of migraine.

• Identify mAbs, particularly CGRP and its receptor, provide effective prophylaxis of migraine.

• Address the need for greater understanding of how to apply new information about migraine pathophysiology to specific patients and potential treatments.

• Review data on the effectiveness and safety of mAbs in the treatment of migraine and learn how results in key subpopulations can help them predict which patients are likely to respond to treatment with CGRP mAbs.

PROGRAM

7:00 am – 7:45 am  Course Registration and Continental Breakfast

7:45 am – 8:00 am  Introduction, Program Overview and Pre-test

8:00 am – 9:00 am  State of the Art

Upon completion of this session, participants will be better able to:

• Review diagnostic criteria for migraine and the progression of episodic migraine to chronic migraine.

• Understand the epidemiology of migraine and the impact of migraine on daily life.

• Discuss migraine pathophysiology.

(cont.)
### PROGRAM (cont.)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 am – 8:20 am</td>
<td>Migraine Diagnosis</td>
</tr>
<tr>
<td></td>
<td>Migraine Epidemiology and Impact</td>
</tr>
<tr>
<td>8:20 am – 8:45 am</td>
<td>Pathophysiologic Foundations of New Therapeutics</td>
</tr>
<tr>
<td>8:45 am – 9:00 am</td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>9:00 am – 10:15 am</td>
<td><strong>Next Generation Acute Treatment: Addressing Unmet Needs</strong></td>
</tr>
<tr>
<td></td>
<td>Upon completion of this session, participants will be better able to:</td>
</tr>
<tr>
<td></td>
<td>• Identify unmet needs and discuss current treatments in acute migraine therapy.</td>
</tr>
<tr>
<td></td>
<td>• Recognize common comorbid conditions reported in migraine and resulting implications for clinical practice.</td>
</tr>
<tr>
<td></td>
<td>• Discuss novel treatments in acute migraine therapy.</td>
</tr>
<tr>
<td>9:00 am – 9:30 am</td>
<td>Unmet Needs, Current Treatment and Novel Approaches to Treatment Delivery</td>
</tr>
<tr>
<td>9:30 am – 10:00 am</td>
<td>Cardiovascular Safety: Ditans, Gepants and Neuromodulation</td>
</tr>
<tr>
<td>10:00 am – 10:15 am</td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>10:15 am – 10:30 am</td>
<td>Break</td>
</tr>
<tr>
<td>10:30 am – 12:00 pm</td>
<td><strong>Next Generation Preventive Treatment</strong></td>
</tr>
<tr>
<td></td>
<td>Upon completion of this session, participants will be better able to:</td>
</tr>
<tr>
<td></td>
<td>• Review current patterns of use of preventive medications.</td>
</tr>
<tr>
<td></td>
<td>• Discuss advantages of new drug targets (eg, mAbs) for preventive therapy.</td>
</tr>
<tr>
<td></td>
<td>• Determine the different neurostimulation techniques available for migraine prevention.</td>
</tr>
<tr>
<td></td>
<td>• Examine behavioral intervention techniques.</td>
</tr>
<tr>
<td>10:30 am – 10:50 am</td>
<td>Current Treatment and Unmet Needs</td>
</tr>
<tr>
<td>10:50 am – 11:10 am</td>
<td>Immunology, Antibodies and Monoclonal Antibodies</td>
</tr>
<tr>
<td>11:10 am – 11:30 am</td>
<td>Anti-CGRP Antibodies and Other Migraine Biologics</td>
</tr>
<tr>
<td>11:30 am – 11:45 am</td>
<td>Behavioral Interventions</td>
</tr>
<tr>
<td>11:45 am – 12:00 pm</td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>12:00 pm – 1:15 pm</td>
<td><strong>Working Lunch: Case Discussions</strong></td>
</tr>
<tr>
<td></td>
<td>All Faculty</td>
</tr>
<tr>
<td>1:15 pm – 1:30 pm</td>
<td>Break</td>
</tr>
</tbody>
</table>
1:30 pm – 4:45 pm  Procedures, Devices and Non-pharmacological Treatment Workshops

Attendees will be broken into two (2) groups. Each group will be assigned a workshop initially and then switch to the other at the break allowing attendees to attend both workshops. Workshop assignment will be noted on the back of the attendee name badge.

CURRICULUM DEVELOPERS

PROGRAM CHAIRS
Richard B. Lipton, MD, FAHS
Albert Einstein College of Medicine

Stephen D. Silberstein, MD, FAHS
Thomas Jefferson University

COMMITTEE
Matthew S. Robbins, MD, FAHS
Weill Cornell Medicine

PROGRAM

1:30 pm – 3:00 pm  Workshop 1: Procedures: Nerve Blocks and OnabotulinumtoxinA

1:30 pm - 2:15 pm  Nerve Blocks and OnabotulinumtoxinA with Q & A
2:15 pm - 3:00 pm  Headache Procedures Hands-on Training

3:00 pm – 3:15 pm  Break
(attendees switch rooms-workshops repeat)

3:15 pm – 4:45 pm  Workshop 1: Procedures: Nerve Blocks and OnabotulinumtoxinA

3:15 pm - 4:00 pm  Nerve Blocks and OnabotulinumtoxinA with Q & A
4:00 pm - 4:45 pm  Headache Procedures Hands-on Training

Upon completion of this session, participants will be better able to:

• Identify patients with headache disorders who are candidates for peripheral nerve blocks, trigger point injections, and onabotulinumtoxinA injections.

• Gain an understanding of anatomical landmarks enabling safe and effective procedural headache therapy.

• Perform peripheral nerve blocks, trigger point injections, and onabotulinumtoxinA injections on models to optimize use in clinical practice.

This Workshop will highlight the role of nerve blocks, stimulators, and OnabotulinumtoxinA in the treatment of migraine and chronic migraine. The workshop will include a didactic session coupled with hands-on training.
1:30 pm – 4:45 pm  Procedures, Devices and Non-pharmacological Treatment Workshops

Attendees will be broken into two (2) groups. Each group will be assigned a workshop initially and then switch to the other at the break allowing attendees to attend both workshops. Workshop assignment will be noted on the back of the attendee name badge.

**CURRICULUM DEVELOPERS**

**PROGRAM CHAIRS**
Richard B. Lipton, MD, FAHS  
Albert Einstein College of Medicine

Stephen D. Silberstein, MD, FAHS  
Thomas Jefferson University

**COMMITTEE**
Dawn C. Buse, PhD, FAHS  
Albert Einstein College of Medicine

Peter J. Goadsby, MD, PhD, FAHS  
University of California San Francisco

**Rashmi B. Halker Singh, MD, FAHS**  
Mayo Clinic Arizona

**PROGRAM**

1:30 pm - 3:00 pm  Workshop 2: Nonpharmacologic Treatments

1:30 pm - 2:15 pm  Devices and Procedures with Q&A

2:15 pm - 3:00 pm  Behavioral Enhancements to Migraine Management with Q & A

3:00 pm - 3:15 pm  Break  
(attendees switch rooms-workshops repeat)

3:15 pm - 4:45 pm  Workshop 2: Nonpharmacologic Treatments

3:15 pm - 4:00 pm  Devices and Procedures with Q&A

4:00 pm - 4:45 pm  Behavioral Enhancements to Migraine Management with Q & A

Upon completion of this session, participants will be better able to:

- Assess patients who have contradictions to standard migraine treatments and may be candidates for alternative treatment strategies.
- Screen and identify patients who fail standard and preventative therapies and may be at risk of developing medication overuse or headache status deterioration.
- Utilize alternative neuromodulating treatments to reduce the severity, disability, and pain associated with migraine and other headache disorders.

This Workshop will review strategies for optimizing medical communication, enhancing patient adherence and self-efficacy, and creating tailored comprehensive treatment plans including empirically supported behavioral approaches.
TARGET AUDIENCE
This program is designed for neurologists, family practitioners, internal medicine, psychologists, and other health professionals who would like more information on the proper diagnosis and treatment of chronic migraine patients.

EDUCATION MISSION STATEMENT
The provision of quality CME is a primary mission of the American Headache Society® (AHS). AHS’s educational objectives are to continue to improve the knowledge, skills, and professional performance of physicians, psychologists, and other health professionals in the care of patients with head, neck, and orofacial pain by:
• Providing a forum for presentation of free scientific communication on research and clinical practice
• Providing educational symposia
• Improving education in medical schools and residency programs
• Identifying and developing new educational initiatives
• Supporting educational programs directed to people with head, neck, and orofacial pain
• Maintaining strict adherence to ACCME guidelines
• Developing educational activities and tools that are designed, and then evaluated, for their role in improving the learners’ competence, performance and the overall quality and safety of the care they give to individuals suffering from head, neck and orofacial pain.

CONTINUING MEDICAL EDUCATION CREDIT
CME Statement: AHS is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians. AHS takes responsibility for the content, quality, and scientific integrity of this CME activity. The American Headache Society® designates this live activity for a maximum of 7.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This Live activity, Next Generation Migraine Therapies, from 03/21/2020 - 05/16/2020, has been reviewed and is acceptable for up to 8.25 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURE STATEMENT
All contributors who can affect American Headache Society CME content (including but not limited to Leadership, Program Chairs, Program Committee Members, Moderators, Faculty, Speakers, Reviewers, Teachers, Authors, Medical Writers and Staff), in their respective roles, are required to disclose all relevant financial relationships with any commercial interest that could be viewed as a real or perceived conflict of interest. Contributors will also identify relevant financial relationships of their spouse, partner or immediate family.

This policy is in effect to maintain adherence with the conflict of interest guidelines set by the Accreditation Council for Continuing Medical Education (ACCME) and the American Headache Society Ethics Committee.

Prior to the program, attendees will be made aware of the presence or absence of relevant financial relationships for any contributors who may affect the development, management, presentation or evaluation of the CME activity. The presence or absence of relevant financial relationships for any contributor who affects content are listed in the Final Program, mobile app (where applicable), presented verbally and in slide form.

Individuals who refuse to disclose relevant financial relationships will be disqualified from being a contributor and cannot have control of, or responsibility for, the development, management presentation or evaluation of the CME activity.

SPECIAL NOTE FOR THE PHYSICALLY CHALLENGED
The American Headache Society® wishes to take steps to ensure that no individual with disability is excluded, denied services, segregated, or otherwise treated differently than other individuals because of the absence of auxiliary aids and services. If you need any auxiliary aids or services identified in the Americans with Disabilities Act, or any assistance in registering for this symposium, please contact AHSHQ at 856-423-0043, write AHS, 19 Mantua Road, Mt. Royal, NJ, 08061, or email AHSHQ@talley.com.

REGISTRATION
To register, at no cost to the healthcare professional, click here.

www.AmericanHeadacheSociety.org